BFG
BCAX

Bleakley Financial Group’s Bicara Therapeutics BCAX Stock Holding History

Bleakley Financial Group’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$866K Sell
29,181
-150
-0.5% -$3.35K 0.01% 689
2026
Q1 		$583K Buy
29,331
+149
+0.5% +$2.56K 0.01% 609
2025
Q4 		$491K Sell
29,182
-1,296
-4% -$22.1K 0.01% 583
2025
Q3 		$481K Buy
+30,478
New +$341K 0.01% 508

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bleakley Financial Group's BCAX Position: Q2 2026 in Review

Bleakley Financial Group reduced its Bicara Therapeutics (BCAX) stake by 0.51% in Q2 2026, selling an estimated $3.35K and leaving 29,181 shares worth $866K. The position accounts for 0.01% of the portfolio, ranked #689.

Bleakley Financial Group first reported a position in BCAX in Q3 2025 and has held it in 4 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Bleakley Financial Group held 29,181 shares of Bicara Therapeutics worth $866K as of Q2 2026.
  • Bleakley Financial Group sold 150 Bicara Therapeutics shares in Q2 2026, an estimated $3.35K.
  • Bicara Therapeutics made up 0.01% of Bleakley Financial Group's portfolio in Q2 2026, its #689 holding.
  • Bleakley Financial Group first reported a position in Bicara Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Bleakley Financial Group's 13F filing for Q2 2026, filed 5 Aug 2026.